Conclusions
In this large retrospective study, the prevalence of most maternal and
infant outcomes was similar with different antihypertensive medications.
A significantly lower risk of SGA was seen for methyldopa than
labetalol, which is noteworthy because methyldopa is not preferred in US
or UK guidelines.6,7Our results suggest that
methyldopa may warrant additional consideration, especially in
pregnancies for which there is heightened concern about growth
restriction.